Effectiveness of a Combination of Nasturtium Herb and Horseradish Root (Angocin<sup>®</sup> <i>Anti-Infekt N</i>) Compared to Antibiotics in Managing Acute and Recurrent Urinary Tract Infections: A Retrospective Real-world Cohort Study
Background: The goal of this study was to evaluate whether the medical recommendation of Angocin<sup>®</sup> <i>Anti-Infekt N</i>, compared to standard antibiotic treatment shortly after the diagnosis of a urinary tract infection (UTI) or cystitis, is negatively associated wi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/13/11/1036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: The goal of this study was to evaluate whether the medical recommendation of Angocin<sup>®</sup> <i>Anti-Infekt N</i>, compared to standard antibiotic treatment shortly after the diagnosis of a urinary tract infection (UTI) or cystitis, is negatively associated with an early, sporadic, or recurrent UTI, subsequent antibiotic prescriptions, pyelonephritis as a renal complication, or UTI-associated sick leave. Methods: This retrospective cohort study was based on data from the IQVIA<sup>TM</sup> Disease Analyzer database and included patients diagnosed with acute UTI or cystitis by physicians in Germany between 2005 and 2021, who were prescribed either Angocin<sup>®</sup> or standard antibiotics within 4 days after diagnosis. Patients prescribed antibiotics were matched to those prescribed Angocin<sup>®</sup> (5:1) using propensity scores. Univariable logistic and Cox regression models were used to investigate the association between Angocin<sup>®</sup> prescription and the defined study outcomes. The effects of Angocin<sup>®</sup> were adjusted for age, sex, insurance status, index diagnosis, and physician specialty. Results: A total of 2277 Angocin<sup>®</sup> patients and 11,385 antibiotic patients were available for analysis. Compared to antibiotic prescriptions, Angocin<sup>®</sup> prescription was associated with significantly lower odds of an early relapse within 1–30 days after the index date (odds ratio (OR): 0.74; 95% confidence interval (CI): 0.62–0.87; <i>p</i> < 0.001), further sporadic UTI within 31–365 days after the index date (OR: 0.68; 95% CI: 0.58–0.78; <i>p</i> < 0.001), and recurrent UTI (OR: 0.63; 95% CI: 0.48–0.82; <i>p</i> < 0.001). This was also accompanied by reduced antibiotic prescriptions (1–30 days: OR: 0.63; 95% CI: 0.53–0.74, <i>p</i> < 0.001; 31–365 days: OR: 0.56; 95% CI: 0.49–0.64, <i>p</i> < 0.001). A strong, but due to the low incidence, not significant, negative association was observed between Angocin<sup>®</sup> prescription and the occurrence of pyelonephritis (hazard ratio (HR): 0.67; 95% CI: 0.43–1.06; <i>p</i> = 0.073). Conclusions: The results of this real-world data study demonstrate that Angocin<sup>®</sup> can be an effective therapeutic option for managing acute and recurrent UTIs and serves as an alternative therapy to antibiotics. |
|---|---|
| ISSN: | 2079-6382 |